Ads
related to: von willebrand disease treatment vwd- Von Willebrand Disease
Learn about the underlying cause of
von Willebrand disease.
- Prophylaxis Information
Find prophylactic information
for this treatment option.
- Surgery Information
See how this treatment is used to
prepare for surgeries.
- Stay Up-to-Date
Stay connected with the latest
updates about VONVENDI®.
- Von Willebrand Disease
Search results
Results from the WOW.Com Content Network
Von Willebrand disease (VWD) is the most common hereditary blood-clotting disorder in humans. An acquired form can sometimes result from other medical conditions. [ 1 ] It arises from a deficiency in the quality or quantity of von Willebrand factor (VWF), a multimeric protein that is required for platelet adhesion .
Vonicog alfa, sold under the brand names Vonvendi and Veyvondi, is a medication used to control bleeding in adults with von Willebrand disease (an inherited bleeding disorder). [6] [5] [7] [8] It is a recombinant von Willebrand factor. [6] [5] The most common adverse reactions are generalized itching, vomiting, nausea, dizziness, and vertigo. [6]
Von Willebrand Disease in dogs is a complex clotting disorder that can vary in symptoms and the risk of genetic inheritance. ... Despite the lack of good treatment options, most dogs with Type 1 ...
Desmopressin (DDAVP) is usually the first line treatment for mild to moderate type 1 von Willebrand disease. [1] It is not recommended in severe disease or in those with abnormal factor VIII. [1] Usefulness in type 2A, 2M, or 2N von Willebrand disease is variable. [1] Generally not recommended in 2B and type 3 von Willebrand disease. [1]
Von Willebrand factor (VWF) (German: [fɔn ˈvɪləbʁant]) is a blood glycoprotein that promotes hemostasis, specifically, platelet adhesion.It is deficient and/or defective in von Willebrand disease and is involved in many other diseases, including thrombotic thrombocytopenic purpura, Heyde's syndrome, and possibly hemolytic–uremic syndrome. [5]
In addition, desmopressin (DDAVP) is known to be effective in people with von Willebrand's disease, [17] [18] including people with valvular heart disease. [19] [20] Desmopressin stimulates release of von Willebrand factor from blood vessel endothelial cells by acting on the V2 receptor, which leads to decreased breakdown of Factor VIII.
It is similar to the ristocetin cofactor assay but has the added benefit in that it helps in the diagnosis of type 2B/pseudo von Willebrand disease (vWD) and Bernard–Soulier syndrome because it uses patient's live endogenous platelets, whereas ristocetin cofactor assay tests the function of only the vWF and not the platelets. Ristocetin ...
In the case of type 2B vWD, the gain-of-function mutation involves von Willebrand's factor (VWF gene), and in platelet-type vWD, the receptor is the object of the mutation (GPIb). This increased binding causes vWD because the high-molecular weight multimers are removed from circulation in plasma since they remain attached to the patient's ...
Ads
related to: von willebrand disease treatment vwd